期刊文献+

Irritable bowel syndrome: Pathogenesis, diagnosis, treatment, and evidence-based medicine 被引量:72

Irritable bowel syndrome: Pathogenesis, diagnosis, treatment, and evidence-based medicine
下载PDF
导出
摘要 Irritable bowel syndrome (IBS) is a chronic and debilitating functional gastrointestinal disorder that affects 9%-23% of the population across the world. The percentage of patients seeking health care related to IBS approaches 12% in primary care practices and is by far the largest subgroup seen in gastroenterology clinics. It has been well documented that these patients exhibit a poorer quality of life and utilize the health care system to a greater degree than patients without this diagnosis. The pathophysiology of IBS is not clear. Many theories have been put forward, but the exact cause of IBS is still uncertain. According to the updated ROME III criteria, IBS is a clinical diagnosis and presents as one of the three predominant subtypes: (1) IBS with constipation (IBS-C); (2) IBS with diarrhea (IBS-D); and (3) mixed IBS (IBS-M); former ROME definitions refer to IBS-M as alternating IBS (IBS-A). Across the IBS subtypes, the presentation of symptoms may vary among patients and change over time. Patients report the most distressing symptoms to be abdominal pain, straining, myalgias, urgency, bloating and feelings of serious illness. The complexity and diversity of IBS presentation makes treatment difficult. Although there are reviews and guidelines for treating IBS, they focus on the efficacy of medications for IBS symptoms using high-priority endpoints, leaving those of lower priority largely unreported. Therefore, the aim of this review is to provide a comprehensive evidence-based review of the diagnosis, pathogenesis and treatment to guide clinicians diagnosing and treating their patients. Irritable bowel syndrome(IBS)is a chronic and debilitating functional gastrointestinal disorder that affects9%-23%of the population across the world.The percentage of patients seeking health care related to IBS approaches 12%in primary care practices and is by far the largest subgroup seen in gastroenterology clinics.It has been well documented that these patients exhibit a poorer quality of life and utilize the health care system to a greater degree than patients without this diagnosis.The pathophysiology of IBS is not clear.Many theories have been put forward,but the exact cause of IBS is still uncertain.According to the updated ROMEⅢcriteria,IBS is a clinical diagnosis and presents as one of the three predominant subtypes:(1)IBS with constipation(IBS-C);(2)IBS with diarrhea(IBS-D);and(3)mixed IBS(IBS-M);former ROME definitions refer to IBS-M as alternating IBS(IBS-A).Across the IBS subtypes,the presentation of symptoms may vary among patients and change over time.Patients report the most distressing symptoms to be abdominal pain,straining,myalgias,urgency,bloating and feelings of serious illness.The complexity and diversity of IBS presentation makes treatment difficult.Although there are reviews and guidelines for treating IBS,they focus on the efficacy of medications for IBS symptoms usinghigh-priority endpoints,leaving those of lower priority largely unreported.Therefore,the aim of this review is to provide a comprehensive evidence-based review of the diagnosis,pathogenesis and treatment to guide clinicians diagnosing and treating their patients.
作者 Lekha Saha
出处 《World Journal of Gastroenterology》 SCIE CAS 2014年第22期6759-6773,共15页 世界胃肠病学杂志(英文版)
关键词 Irritable bowel syndrome PATHOGENESIS DIAGNOSIS TREATMENT Evidence-based medicine Irritable bowel syndrome Pathogenesis Diagnosis Tr
  • 相关文献

参考文献11

  • 1Xiao-Peng Ma Lin-Ying Tan Yun Yang Huan-Gan Wu Bin Jiang Hui-Rong Liu Ling Yang.Effect of electro-acupuncture on substance P, its receptor and corticotropin-releasing hormone in rats with irritable bowel syndrome[J].World Journal of Gastroenterology,2009,15(41):5211-5217. 被引量:50
  • 2J. Matricon,M. Meleine,A. Gelot,T. Piche,M. Dapoigny,E. Muller,D. Ardid.Review article: associations between immune activation, intestinal permeability and the irritable bowel syndrome[J].Aliment Pharmacol Ther (pt).2012(11pt12)
  • 3Kaitlin Occhipinti,James Smith.Irritable Bowel Syndrome: A Review and Update[J].Clinics in Colon and Rectal Surgery.2012(01)
  • 4Alexander C Ford,Nicholas J Talley.Irritable bowel syndrome[J].BMJ (sep ).2012(sep041)
  • 5Brennan M.R. Spiegel.Questioning the Bacterial Overgrowth Hypothesis of Irritable Bowel Syndrome: An Epidemiologic and Evolutionary Perspective[J].Clinical Gastroenterology and Hepatology.2011(6)
  • 6Derrick KOng,Shaylyn BMitchell,Jacqueline SBarrett,Sue JShepherd,Peter MIrving,Jessica RBiesiekierski,StuartSmith,Peter RGibson,Jane GMuir.Manipulation of dietary short chain carbohydrates alters the pattern of gas production and genesis of symptoms in irritable bowel syndrome[J].Journal of Gastroenterology and Hepatology.2010(8)
  • 7Shahin Merat,Shadi Khalili,Pardise Mostajabi,Anahita Ghorbani,Reza Ansari,Reza Malekzadeh.The Effect of Enteric-Coated, Delayed-Release Peppermint Oil on Irritable Bowel Syndrome[J].Digestive Diseases and Sciences.2010(5)
  • 8William D. Heizer,Susannah Southern,Susan McGovern.The Role of Diet in Symptoms of Irritable Bowel Syndrome in Adults: A Narrative Review[J].Journal of the American Dietetic Association.2009(7)
  • 9Marroon Thabane,John K Marshall.Post-infectious irritable bowel syndrome[J].World Journal of Gastroenterology,2009,15(29):3591-3596. 被引量:25
  • 10En-hua Zhou,Hui-rong Liu,Huan-gan Wu,Yin Shi,Xiao-mei Wang,Lin-ying Tan,Li-qing Yao,Yun-shi Zhong,Yan Jiang,Ling-ling Zhang.Suspended moxibustion relieves chronic visceral hyperalgesia via serotonin pathway in the colon[J].Neuroscience Letters.2009(2)

二级参考文献77

  • 1杨云生,周殿元,张万岱,张振书,宋于刚.肠易激综合征回盲部肥大细胞的研究[J].中华内科杂志,1997,36(4):231-233. 被引量:47
  • 2Drossman DA.The functional gastrointestinal disorders and the Rome III process.Gastroenterology 2006; 130:1377-1390.
  • 3Hasler WL,Owyang C.Irritable bowel syndrome.In:Yamada T,ed.Textbook of Gastroenterology.2nd ed.Philadelphia:Lippincott,1995:1832-1855.
  • 4Dunlop SP,Jenkins D,Spiller RC.Distinctive clinical,psychological,and histological features of postinfective irritable bowel syndrome.Am J Gastroenterol 2003; 98:1578-1583.
  • 5Kim HS,Kim MS,Ji SW,Park H.[The development of irritable bowel syndrome after Shigella infection:3 year follow-up study] Korean J Gastroenterol 2006; 47:300-305.
  • 6Ilnyckyj A,Balachandra B,Elliott L,Choudhri S,Duerksen DR.Post-traveler's diarrhea irritable bowel syndrome:a prospective study.Am J Gastroenterol 2003; 98:596-599.
  • 7Rodríguez LA,Ruigómez A.Increased risk of irritable bowel syndrome after bacterial gastroenteritis:cohort study.BMJ 1999; 318:565-566.
  • 8Ruigómez A,García Rodríguez LA,Panés J.Risk of irritable bowel syndrome after an episode of bacterial gastroenteritis in general practice:influence of comorbidities.Clin Gastroenterol Hepatol 2007; 5:465-469.
  • 9Soyturk M,Akpinar H,Gurler O,Pozio E,Sari I,Akar S,Akarsu M,Birlik M,Onen F,Akkoc N.Irritable bowel syndrome in persons who acquired trichinellosis.Am J Gastroenterol 2007; 102:1064-1069.
  • 10Piche T,Vanbiervliet G,Pipau FG,Dainese R,Hébuterne X,Rampal P,Collins SM.Low risk of irritable bowel syndrome after Clostridium difficile infection.Can J Gastroenterol 2007; 21:727-731.

共引文献86

同被引文献725

引证文献72

二级引证文献787

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部